Please login to the form below
Orencia
This page shows the latest Orencia news and features for those working in and with pharma, biotech and healthcare.
Opdivo drives growth at BMS, but US sales slow down
Overall, BMS reported fourth-quarter revenues up 22% to $5.2bn, with a solid showing from novel oral anticoagulant Eliquis (apixaban), which leaped 57% to $346m and rheumatoid arthritis therapy Orencia
Latest news
-
Opdivo drives gain in BMS sales, but business revamp coming
Away from cancer, rheumatoid arthritis treatment Orencia (abatacept) continued its buoyant run with an 18% increase to $572m, while novel oral anticoagulant Eliquis (apixaban) brought in $884m, a rise of 90%.
-
Shire gives up on Momenta-partnered Humira biosimilar
It also has a biosimilar collaboration with generics giant Mylan covering six biologics, headed by M834, a biosimilar version of Bristol-Myers Squibb's rheumatoid arthritis drug Orencia (abatacept).
-
Mylan buys into six biosimilars, including Orencia candidate
Mylan buys into six biosimilars, including Orencia candidate. Deal with Momenta bolsters biosimilars pipeline for new products. ... The agreement gives Mylan the rights to six biosimilars in Momenta's pipeline, including a version of Bristol-Myers
-
NICE backs four treatments for juvenile idiopathic arthritis
NICE backs four treatments for juvenile idiopathic arthritis. Includes BMS' Orencia and AbbVie's Humira. ... The institute backed Bristol-Myers Squibb's Orencia (abatacept), AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept) and Roche's RoActemra
-
NICE backs biosimilars in rheumatoid arthritis guidance
Orencia (abatacept) and MSD/J&J's Remicade (infliximab).
More from news
Approximately 10 fully matching, plus 33 partially matching documents found.
Latest Intelligence
-
Deal Watch January 2016
255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept).
-
Biosimilars - the same, but different?
Orencia and Actemra for rheumatoid arthritis.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest appointments
-
BMS’ Brian Daniels to retire
Dr Daniels has been with BMS since 2000 as VP of the immunology, pulmonary, and dermatology therapeutic area where he worked on such compounds as rheumatoid arthritis drug Orencia (abatacept).
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Brand leaders in RA will lose market share, predict rheumatologists
market leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Medical/ Scientific Director
-
Salary TBC
-
Account Manager / Account Director
-
Competative
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Account Manager / Senior Account Manager
-
35, 000-40, 000
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Senior Systematic Review Analyst - Oxford
-
Negotiable
-
Account Director
-
£48, 000 - £60, 000
- Digital Manager, London – Healthcare Brandcomms, Medcomms, PR
-
Excellent package
- Senior Account Executive, London, Medical Communications
-
Excellent package
-
Medical Writers
-
Competitive Salary and Benefits
- Events Manager – Med Comms – Surrey
-
Salary TBC
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
-
Associate Director
-
£75, 000-90, 000
Subscribe to our email news alerts
- Oral Appliances lead Sleep Apnea Devices Market Growth, Shows Recent Analysis
- Animal Healthcare Market is poised to cross USD 36 billion by 2024
- Fishawack launches new website and introduces new structure for growth
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- Orphan drugs from Biogen and Amicus win UK Prix Galien
- AZ’s MYSTIC survival data is in – and it’s a bust
PMHub
Market Access Transformation
Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...
Latest intelligence
- OUTiCO win Best in UK Pharmaceutical Outsourcing award
- The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
- Artificial Intelligence in Healthcare
- Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
- World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
- Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
Quick links
Infographics
